These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 18405005)

  • 1. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
    van den Eynde B
    Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of tumor cell-based vaccines.
    Copier J; Dalgleish A
    Int Rev Immunol; 2006; 25(5-6):297-319. PubMed ID: 17169778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New frontiers in cell-based immunotherapy of cancer.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Processing and presentation of tumor antigens and vaccination strategies.
    van der Bruggen P; Van den Eynde BJ
    Curr Opin Immunol; 2006 Feb; 18(1):98-104. PubMed ID: 16343880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [General principles and first clinical trials of therapeutic vaccines against cancer].
    Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
    Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy targeting the telomerase reverse transcriptase.
    Huo LF; Tang JW; Huang JJ; Huang PT; Huang CF; Kung HF; Lin MC
    Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexes.
    Clark CE; Vonderheide RH
    Clin Cancer Res; 2005 Aug; 11(15):5333-6. PubMed ID: 16061844
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in human tumour immunology and immunotherapy.
    Rosenberg SA
    Nature; 2001 May; 411(6835):380-4. PubMed ID: 11357146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune therapy against tumors based on the ubiquitin-proteasome pathway].
    Himeno K; Hisaeda H
    Fukuoka Igaku Zasshi; 2007 Aug; 98(8):312-9. PubMed ID: 17907447
    [No Abstract]   [Full Text] [Related]  

  • 15. Antigens for cancer immunotherapy.
    Neller MA; López JA; Schmidt CW
    Semin Immunol; 2008 Oct; 20(5):286-95. PubMed ID: 18951039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
    Neeson P; Paterson Y
    Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
    Ganss R; Arnold B; Hämmerling GJ
    Eur J Immunol; 2004 Oct; 34(10):2635-41. PubMed ID: 15368278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cyclins: a family of widely expressed tumor antigens?
    von Bergwelt-Baildon MS; Kondo E; Klein-González N; Wendtner CM
    Expert Rev Vaccines; 2011 Mar; 10(3):389-95. PubMed ID: 21434806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.